Mobocertinib
Mobocertinib (TAK-788) is a selective, small-molecule EGFR inhibitor developed as an antineoplastic agent. It is utilized in preclinical and clinical research, particularly for targeting EGFR exon 20 insertion mutations in non-small cell lung cancer models, both in vitro and in vivo.
Product Specifications
CAS Number
1847461-43-1
Product Name Alternative
CUTO14, AP32788, AP-32788, AP 32788, A431, Mobocertinib, NSCLC, LU0387, Inhibitor, inhibit, ErbB-1, Epidermal growth factor receptor, EGFRex20ins, EGFR, H1975, HER1, HCC4011, HCC827, tak788, TAK-788, TAK 788
Field of Research
Cardiovascular Research, Signal Transduction
Purity
98.66% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (1.71 mM) ; DMSO:5 mg/mL (8.54 mM)
Smiles
COc1cc (N (C) CCN (C) C) c (NC (=O) C=C) cc1Nc1ncc (C (=O) OC (C) C) c (n1) -c1cn (C) c2ccccc12
Molecular Formula
C32H39N7O4
Molecular Weight
585.7
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
36-1038-100 100 µg
Monoclonal Antibody to HCG-beta (Pregnancy & Choriocarcinoma Marker) (Clone : SPM105)
Sign In for Pricing
View Details 